RaySearch, GE Healthcare collaborate to improve radiation oncology treatment planning

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

GSK and LTZ Therapeutics, an immunotherapy-focused biotechnology company based in Redwood City, CA, will collaborate to advance the development of novel myeloid cell engagers.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Freenome, an early cancer detection company, and Roche announced a collaboration agreement to commercialize Freenome’s cancer screening technology in international markets.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Microsoft and Qure.ai announced a collaboration that will streamline deployment of Qure.ai solutions to hospitals and health systems across the U.S.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.

November 14, 2025

Vol.51 No.42

Clinical Roundup

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Using intraoperative radiation to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Five-treatment radiation regimen poised to become standard of care, phase III data show

Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis.

October 10, 2025

Vol.51 No.37

RaySearch, GE Healthcare collaborate to improve radiation oncology treatment planning

YOU MAY BE INTERESTED IN

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Five-treatment radiation regimen poised to become standard of care, phase III data show

Renew today!

Subscriber content

Never miss an issue!

Login